Ajanta Pharma Share Price
Sector: Biotechnology & Drugs
2781.90 +104.70 (3.91%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2680.00
Today’s High
2787.95
52 Week Low
2022.05
52 Week High
3485.75
2775.20 +99.20 (3.71%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2680.10
Today’s High
2790.60
52 Week Low
2079.95
52 Week High
3485.00
Key Metrics
- Market Cap (In Cr) 34749.3
- Beta 0.41
- Div. Yield (%) 1.05
- P/B 9.45
- TTM P/E 41
- Peg Ratio 4.17
- Sector P/E 26.62
- Open Price 2680
- Prev Close 2677.2
Ajanta Pharma Analysis
Price Analysis
-
1 Week-0.69%
-
3 Months-4.31%
-
6 Month-9.88%
-
YTD-8.74%
-
1 Year25.05%
Risk Meter
- 41% Low risk
- 41% Moderate risk
- 41% Balanced Risk
- 41% High risk
- 41% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 3
- 2
- Buy
- 4
- 4
- 3
- 3
- Hold
- 0.00
- 0.00
- 0.00
- 1
- Sell
- 1
- 1
- 1
- 1
- Strong Sell
- 1
- 1
- 1
- 2
- Total
- 10
- 10
- 8
- 9
Ajanta Pharma News
Ajanta Pharmaceuticals Q2 Results Live: Profit Rises by 10.84% YoY
1 min read . 29 Oct 2024Top events on Oct 28: Spanish PM at Vadodara road show, Q2 results, more
2 min read . 28 Oct 2024Shares to buy or sell: Rajesh Palviya suggests 3 stocks to buy today - October 4
3 min read . 04 Oct 2024Ajanta Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 4208.71
- Selling/ General/ Admin Expenses Total
- 1858.41
- Depreciation/ Amortization
- 135.4
- Other Operating Expenses Total
- 46.95
- Total Operating Expense
- 3156.08
- Operating Income
- 1052.63
- Net Income Before Taxes
- 1113.93
- Net Income
- 816.17
- Diluted Normalized EPS
- 64.97
- Period
- 2024
- Total Assets
- 4638.39
- Total Liabilities
- 1071.03
- Total Equity
- 3567.36
- Tangible Book Valueper Share Common Eq
- 282.15
- Period
- 2024
- Cashfrom Operating Activities
- 785.07
- Cashfrom Investing Activities
- 65.39
- Cashfrom Financing Activities
- -1051.06
- Net Changein Cash
- -200.6
- Period
- 2023
- Total Revenue
- 3742.64
- Selling/ General/ Admin Expenses Total
- 1774.38
- Depreciation/ Amortization
- 130.31
- Other Operating Expenses Total
- 40.13
- Total Operating Expense
- 3062.04
- Operating Income
- 680.6
- Net Income Before Taxes
- 745.25
- Net Income
- 587.98
- Diluted Normalized EPS
- 46.27
- Period
- 2023
- Total Assets
- 4679.02
- Total Liabilities
- 1291.03
- Total Equity
- 3387.99
- Tangible Book Valueper Share Common Eq
- 268.45
- Period
- 2023
- Cashfrom Operating Activities
- 791.78
- Cashfrom Investing Activities
- -559.6
- Cashfrom Financing Activities
- -107.87
- Net Changein Cash
- 124.31
- Period
- 2022
- Total Revenue
- 3340.99
- Selling/ General/ Admin Expenses Total
- 1481.72
- Depreciation/ Amortization
- 124.82
- Other Operating Expenses Total
- 35.39
- Total Operating Expense
- 2533.12
- Operating Income
- 807.87
- Net Income Before Taxes
- 909.48
- Net Income
- 712.69
- Diluted Normalized EPS
- 55.44
- Period
- 2022
- Total Assets
- 4055.58
- Total Liabilities
- 791.24
- Total Equity
- 3264.34
- Tangible Book Valueper Share Common Eq
- 251.82
- Period
- 2022
- Cashfrom Operating Activities
- 562.04
- Cashfrom Investing Activities
- -74.1
- Cashfrom Financing Activities
- -460.04
- Net Changein Cash
- 27.9
- Period
- 2021
- Total Revenue
- 2889.69
- Selling/ General/ Admin Expenses Total
- 1171.06
- Depreciation/ Amortization
- 115.6
- Other Operating Expenses Total
- 27.91
- Total Operating Expense
- 2005.01
- Operating Income
- 884.68
- Net Income Before Taxes
- 900.18
- Net Income
- 653.87
- Diluted Normalized EPS
- 50.6
- Period
- 2021
- Total Assets
- 3778.72
- Total Liabilities
- 783.09
- Total Equity
- 2995.63
- Tangible Book Valueper Share Common Eq
- 229.96
- Period
- 2021
- Cashfrom Operating Activities
- 576.31
- Cashfrom Investing Activities
- -282.39
- Cashfrom Financing Activities
- -318.29
- Net Changein Cash
- -24.37
- Period
- 2020
- Total Revenue
- 2587.87
- Selling/ General/ Admin Expenses Total
- 1179.7
- Depreciation/ Amortization
- 95.23
- Other Operating Expenses Total
- 26.25
- Total Operating Expense
- 2004.08
- Operating Income
- 583.79
- Net Income Before Taxes
- 663.97
- Net Income
- 467.7
- Diluted Normalized EPS
- 36.39
- Period
- 2020
- Total Assets
- 3318.69
- Total Liabilities
- 719.82
- Total Equity
- 2598.87
- Tangible Book Valueper Share Common Eq
- 197.66
- Period
- 2020
- Cashfrom Operating Activities
- 456.77
- Cashfrom Investing Activities
- -224.41
- Cashfrom Financing Activities
- -128.63
- Net Changein Cash
- 103.73
- Period
- 2019
- Total Revenue
- 2055.37
- Selling/ General/ Admin Expenses Total
- 842.08
- Depreciation/ Amortization
- 72.08
- Other Operating Expenses Total
- 67.62
- Total Operating Expense
- 1560.79
- Operating Income
- 494.58
- Net Income Before Taxes
- 514.27
- Net Income
- 386.97
- Diluted Normalized EPS
- 29.81
- Period
- 2019
- Total Assets
- 2696.18
- Total Liabilities
- 450.97
- Total Equity
- 2245.21
- Tangible Book Valueper Share Common Eq
- 171.04
- Period
- 2019
- Cashfrom Operating Activities
- 374.78
- Cashfrom Investing Activities
- -222.8
- Cashfrom Financing Activities
- -147.46
- Net Changein Cash
- 4.52
- Period
- 2024-12-31
- Total Revenue
- 1146.13
- Selling/ General/ Admin Expenses Total
- 265.17
- Depreciation/ Amortization
- 35.97
- Other Operating Expenses Total
- 302.32
- Total Operating Expense
- 861.27
- Operating Income
- 284.86
- Net Income Before Taxes
- 307.39
- Net Income
- 232.88
- Diluted Normalized EPS
- 18.59
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1186.64
- Selling/ General/ Admin Expenses Total
- 260.96
- Depreciation/ Amortization
- 34.39
- Other Operating Expenses Total
- 327.18
- Total Operating Expense
- 884.21
- Operating Income
- 302.43
- Net Income Before Taxes
- 290.24
- Net Income
- 216.48
- Diluted Normalized EPS
- 17.26
- Period
- 2024-09-30
- Total Assets
- 4790.5
- Total Liabilities
- 1113.55
- Total Equity
- 3676.95
- Tangible Book Valueper Share Common Eq
- 293.3
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 776.46
- Cashfrom Investing Activities
- -475.69
- Cashfrom Financing Activities
- -365.99
- Net Changein Cash
- -65.22
- Period
- 2024-06-30
- Total Revenue
- 1144.92
- Selling/ General/ Admin Expenses Total
- 283.78
- Depreciation/ Amortization
- 33.97
- Other Operating Expenses Total
- 262.94
- Total Operating Expense
- 848.54
- Operating Income
- 296.38
- Net Income Before Taxes
- 322.12
- Net Income
- 245.77
- Diluted Normalized EPS
- 19.53
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1054.08
- Selling/ General/ Admin Expenses Total
- 233.51
- Depreciation/ Amortization
- 34.25
- Other Operating Expenses Total
- 277.87
- Total Operating Expense
- 810.01
- Operating Income
- 244.07
- Net Income Before Taxes
- 278.04
- Net Income
- 202.72
- Diluted Normalized EPS
- 16.09
- Period
- 2024-03-31
- Total Assets
- 4638.39
- Total Liabilities
- 1071.03
- Total Equity
- 3567.36
- Tangible Book Valueper Share Common Eq
- 282.15
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 785.07
- Cashfrom Investing Activities
- 65.39
- Cashfrom Financing Activities
- -1051.06
- Net Changein Cash
- -200.6
- Period
- 2023-12-31
- Total Revenue
- 1105.15
- Selling/ General/ Admin Expenses Total
- 231.35
- Depreciation/ Amortization
- 34.26
- Other Operating Expenses Total
- 257.98
- Total Operating Expense
- 817.76
- Operating Income
- 287.39
- Net Income Before Taxes
- 290.91
- Net Income
- 210.03
- Diluted Normalized EPS
- 16.67
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1028.44
- Selling/ General/ Admin Expenses Total
- 222.27
- Depreciation/ Amortization
- 33.71
- Other Operating Expenses Total
- 259.39
- Total Operating Expense
- 771.49
- Operating Income
- 256.95
- Net Income Before Taxes
- 275.94
- Net Income
- 195.3
- Diluted Normalized EPS
- 15.5
- Period
- 2023-09-30
- Total Assets
- 4433.23
- Total Liabilities
- 951.36
- Total Equity
- 3481.87
- Tangible Book Valueper Share Common Eq
- 275.8
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 399.03
- Cashfrom Investing Activities
- 245.93
- Cashfrom Financing Activities
- -713.74
- Net Changein Cash
- -68.78
- Period
- 2023-06-30
- Total Revenue
- 1021.04
- Selling/ General/ Admin Expenses Total
- 213.21
- Depreciation/ Amortization
- 33.18
- Other Operating Expenses Total
- 274.62
- Total Operating Expense
- 772.91
- Operating Income
- 248.13
- Net Income Before Taxes
- 269.04
- Net Income
- 208.12
- Diluted Normalized EPS
- 16.53
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 881.84
- Selling/ General/ Admin Expenses Total
- 223.64
- Depreciation/ Amortization
- 33.02
- Other Operating Expenses Total
- 221.7
- Total Operating Expense
- 719.26
- Operating Income
- 162.58
- Net Income Before Taxes
- 152.05
- Net Income
- 122.25
- Diluted Normalized EPS
- 9.54
- Period
- 2023-03-31
- Total Assets
- 4679.02
- Total Liabilities
- 1291.03
- Total Equity
- 3387.99
- Tangible Book Valueper Share Common Eq
- 268.45
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 791.78
- Cashfrom Investing Activities
- -559.6
- Cashfrom Financing Activities
- -107.87
- Net Changein Cash
- 124.31
- Period
- 2022-12-31
- Total Revenue
- 971.77
- Selling/ General/ Admin Expenses Total
- 192.42
- Depreciation/ Amortization
- 33.3
- Other Operating Expenses Total
- 303.48
- Total Operating Expense
- 798.53
- Operating Income
- 173.24
- Net Income Before Taxes
- 168.34
- Net Income
- 134.51
- Diluted Normalized EPS
- 10.5
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Ajanta Pharma Technical
Moving Average
SMA
- 5 Day2701.68
- 10 Day2649.52
- 20 Day2622.83
- 50 Day2604.3
- 100 Day2732.78
- 300 Day2835.94
Ajanta Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Ipca Laboratories
- 1413.65
- -4.1
- -0.29
- 1757.65
- 1060.95
- 36055.34
- Laurus Labs
- 626.45
- 1.05
- 0.17
- 660.9
- 386.85
- 33781.47
- Ajanta Pharma
- 2781.9
- 104.7
- 3.91
- 3485.75
- 2022.05
- 34749.3
- Suven Pharmaceuticals
- 1154
- 10.75
- 0.94
- 1359
- 597
- 29495.48
- Piramal Pharma
- 214.95
- -1.05
- -0.49
- 307.85
- 135.85
- 28431.14
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Ipca Laboratories
- 54.89
- 5.69
- 14.98
- 12.25
- Laurus Labs
- 94.22
- 7.54
- 18.12
- 11.88
- Ajanta Pharma
- 41.19
- 9.45
- 21.37
- 19.31
- Suven Pharmaceuticals
- 96.12
- 14.19
- 27.91
- 33.21
- Piramal Pharma
- 470.1
- 3.62
- -
- -
Ajanta Pharma Shareholding
Shareholding Pattern
*Promoter pledging: 8.36%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 30-Apr-25
- Audited Results & A.G.M.
- 30-Jan-25
- Quarterly Results
- 28-Oct-24
- Quarterly Results
- 30-Jul-24
- Quarterly Results
- 02-May-24
- Audited Results & Buy Back of Shares
- 31-Jan-24
- Quarterly Results & 2nd Interim Dividend
- 31-Oct-23
- Quarterly Results
- 27-Jul-23
- Quarterly Results
- 05-May-23
- Audited Results
- 10-Mar-23
- Buy Back of shares
- Meeting Date
- Announced on
- Purpose
- 18-Jul-24
- 14-Jun-24
- AGM
- 30-May-24
- 02-May-24
- Others
- 18-Jul-23
- 05-May-23
- AGM
- 11-Mar-23
- 07-Feb-23
- POM
- 04-Aug-22
- 21-Jun-22
- AGM
- 14-Jul-21
- 03-Jun-21
- AGM
- -
- 28-Dec-21
- Others
- -
- 10-Mar-23
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 25-Oct-24
- 06-Nov-24
- 06-Nov-24
- 28
- 25-Jan-24
- 08-Feb-24
- 08-Feb-24
- 26
- 24-Jul-23
- 04-Aug-23
- 04-Aug-23
- 15
- 25-Jul-23
- 04-Aug-23
- 04-Aug-23
- 10
- 02-Nov-22
- 14-Nov-22
- 11-Nov-22
- 7
- 21-Oct-21
- 10-Nov-21
- 09-Nov-21
- 9.5
- Announced on
- Record Date
- Ex-Bonus
- Description
- 10-May-22
- 23-Jun-22
- 22-Jun-22
- Bonus issue in the ratio of 1:2 of Rs. 2/-.

